BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma.
Abe
M
M
Kido
S
S
Hiasa
M
M
Nakano
A
A
Oda
A
A
Amou
H
H
Matsumoto
T
T
D053264:B-Cell Activating Factor / Q000502:physiology*; D002470:Cell Survival / Q000502:physiology; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000235:genetics / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology*; D010010:Osteoclasts / Q000502:physiology; D053303:Transmembrane Activator and CAML Interactor Protein / Q000235:genetics / Q000627:therapeutic use*; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13 / Q000502:physiology*
D053264:B-Cell Activating Factor; D007141:Immunoglobulin Fc Fragments; C505719:TNFSF13B protein, human; D053303:Transmembrane Activator and CAML Interactor Protein; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13